论文部分内容阅读
[目的]探讨硼替佐米、地塞米松联合治疗多发性骨髓瘤的临床疗效及安全性。[方法]选取2008年6月~2009年12月在我科经硼替佐米联合地塞米松(VD)治疗的多发性骨髓瘤(MM)患者16例作为VD组,并选取同期在我科经VAD(长春瑞宾+阿霉素+地塞米松)治疗的25例MM患者作为VAD组,观察两组治疗效果及安全性,并对VD治疗方案在初治和复发患者中疗效、轻链型和非轻链型患者中的疗效进行对比分析。[结果]VD组总有效率为87.50%,明显高于VAD组的48.00%,组间比较差异有统计学意义(P﹤0.05);VD组在初治和复发MM患者中疗效相当,在轻链型患者中CR率高于非轻链型患者;VD组不良反应轻微,均为可逆性。[结论]VD化疗方案治疗MM,具有疗效好、不良反应小等优点,是目前治疗MM的一种较佳化疗方案,值得临床推广应用。
[Objective] To explore the clinical efficacy and safety of bortezomib and dexamethasone in the treatment of multiple myeloma. [Methods] Sixteen patients with multiple myeloma (MM) treated with bortezomib and dexamethasone (VD) in our department from June 2008 to December 2009 were selected as the VD group, and the same period in our department VAD (vinorelbine + doxorubicin + dexamethasone) treatment of 25 patients with MM as the VAD group, the treatment effect and safety of the two groups were observed, and the treatment of VD in patients with initial and recurrence of efficacy, light chain And non-light-chain patients in the efficacy of comparative analysis. [Results] The total effective rate of VD group was 87.50%, which was significantly higher than that of VAD group (48.00%), the difference between the two groups was statistically significant (P <0.05) The CR rate in patients with CHD was higher than that in non-CHD patients. The AD patients had mild adverse reactions and all were reversible. [Conclusion] VD chemotherapy regimen has the advantages of good curative effect and small adverse reaction. It is a better chemotherapy regimen for treating MM and is worthy of clinical application.